Advertisement

Topics

Mylan, Like Other Generic Drug Makers, Feels the Pricing Pain

16:00 EDT 10 Aug 2017 | PharmPro

Given pricing challenges and an uncertain U.S. regulatory environment, Mylan plans to defer all major U.S. launches from its full year 2017 financial guidance to 2018, including the Advair and Copaxone generics, according to CEO Heather Bresch.
Contributed Author: 
Associated Press
Topics: 

Original Article: Mylan, Like Other Generic Drug Makers, Feels the Pricing Pain

NEXT ARTICLE

More From BioPortfolio on "Mylan, Like Other Generic Drug Makers, Feels the Pricing Pain"

Quick Search
Advertisement